Adaptimmune Therapeutics PLC — Director's Dealing 2019

Aug 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-08-01

Reporting Person: Lunger John (Chief Patient Supply Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-08-01	Option to purchase Ordinary Shares	$0.55	A	839568	Acquired	2029-08-01	Ordinary Shares (839568)	Direct
2019-08-01	Option to purchase Ordinary Shares	$0.0012	A	187500	Acquired		Ordinary Shares (187500)	Direct

Footnotes

F1: The exercise price was converted from GBP0.45 based on an exchange rate of U.S.$1.22179 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 209,892 Ordinary Shares on August 1, 2020 and will be exercisable as to the remainder in monthly installments of 17,490 Ordinary Shares on the first of each month from September 1, 2020 through July 1, 2023 and 17,526 Ordinary Shares on August 1, 2023.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.22179 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 46,875 Ordinary Shares on August 1, 2020 and will be exercisable as to the remainder in annual installments of 46,875 Ordinary Shares on the first of each August from August 1, 2021 through August 1, 2023.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.